Literature DB >> 29475576

Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.

Kannan Sridharan1, Gowri Sivaramakrishnan2.   

Abstract

Sialorrhea is a common distress associated with certain neurological disorders. The aim of this study is to compare the pharmacological agents used for treating sialorrhea by network meta-analysis. Electronic databases were searched for randomized clinical trials comparing active drugs with either placebo or other active drugs. Total drooling scores was the primary outcome measure. Inverse variance heterogeneity model was used for both direct and mixed treatment comparison analysis. Twenty one studies were included in the systematic review and 15 in the meta-analysis. Compared to placebo, benztropine, botulinum toxins A and B are associated with a significant reduction in the frequency and severity of drooling both in the overall neurological disorders as well as for children with cerebral palsy. Only botulinum toxin A and B were associated with significant therapeutic effects in Parkinson's disease. Benztropine and botulinum toxins A and B were observed to be effective in reducing sialorrhea associated with neurological disorders.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Benztropine; Botulinum toxin; Cerebral palsy; Glycopyrrolate; Parkinson’s disease; Scopolamine

Mesh:

Substances:

Year:  2018        PMID: 29475576     DOI: 10.1016/j.jocn.2018.02.011

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Current Aspects of Treatment Options of Chronic Sialorrhea in Children.

Authors:  Stefan Bittmann; Elisabeth Luchter; Lara Bittmann; Elena Moschuring-Alieva; Gloria Villalon
Journal:  J Clin Med Res       Date:  2022-06-27

2.  Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.

Authors:  Javier Martínez-Poles; Velina Nedkova-Hristova; José Bernardo Escribano-Paredes; Sebastián García-Madrona; Elena Natera-Villalba; Carlos Estévez-Fraga; José Luis López-Sendón Moreno; Icíar Avilés-Olmos; Gema Sánchez Díaz; Juan Carlos Martínez Castrillo; Araceli Alonso-Canovas
Journal:  Toxins (Basel)       Date:  2018-05-28       Impact factor: 4.546

3.  Changes in severity and impact of drooling after submandibular gland botulinum neurotoxin A injections in children with neurodevelopmental disabilities.

Authors:  Karen Van Hulst; Jan Jw Van Der Burg; Peter H Jongerius; Alexander Ch Geurts; Corrie E Erasmus
Journal:  Dev Med Child Neurol       Date:  2019-11-14       Impact factor: 5.449

4.  Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions.

Authors:  Koji Makino; Neil Mahant; Dominic Tilden; Lara Aghajanian
Journal:  Neurol Ther       Date:  2020-03-12

5.  Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience.

Authors:  Davide Zanon; Cristina Tumminelli; Anna Maria Chiara Galimberti; Lucio Torelli; Alessandra Maestro; Egidio Barbi; Natalia Maximova
Journal:  Ital J Pediatr       Date:  2021-11-06       Impact factor: 2.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.